Published in Drug Saf Case Rep on September 20, 2017
Cutaneous and ocular reactions to practolol. Br Med J (1974) 8.65
In defense of case reports and case series. Ann Intern Med (2001) 7.99
Genetic control of isoniazid metabolism in man. Br Med J (1960) 7.86
Systemic lupus erythematosus syndrome induced by practolol. Br Med J (1973) 6.59
Fatal cholestatic jaundice in elderly patients taking benoxaprofen. Br Med J (Clin Res Ed) (1982) 4.11
Torsades de pointes occurring in association with terfenadine use. JAMA (1990) 3.93
Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol (1979) 3.78
Exfoliative dermatitis and practolol. Lancet (1972) 3.77
Untoward effects associated with practolol administration: oculomucocutaneous syndrome. Br Med J (1975) 3.33
Mechanism of the cardiotoxic actions of terfenadine. JAMA (1993) 3.27
Neuropathy after intake of thalidomide (distaval). Br Med J (1961) 2.84
Case reports of suspected adverse drug reactions--systematic literature survey of follow-up. BMJ (2006) 2.79
Practolol-induced drug eruption. Proc R Soc Med (1973) 2.62
Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J (Clin Res Ed) (1982) 2.39
Guidelines for submitting adverse event reports for publication. Drug Saf (2007) 2.38
Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol (2001) 1.88
The use of evidence in pharmacovigilance. Case reports as the reference source for drug withdrawals. Eur J Clin Pharmacol (2001) 1.79
PROBLEMS RAISED FOR THE FDA BY THE OCCURRENCE OF THALIDOMIDE EMBRYOPATHY IN GERMANY, 1960-1961. Am J Public Health Nations Health (1965) 1.69
Torsades de pointes ventricular tachycardia and terodiline. Lancet (1991) 1.59
INSUFFICIENT PARAPHYDROXYLATION AS A CAUSE OF DIPHENYLHYDANTOIN TOXICITY. Neurology (1964) 1.57
Hypotensive response to debrisoquine and hydroxylation phenotype. Life Sci (1978) 1.55
Torsades de pointes complicating treatment with terodiline. BMJ (1991) 1.54
Letter: Skin reactions to practolol. Br Med J (1974) 1.48
A within-patient comparison of debrisoquine and methyldopa in hypertension. Br Med J (1971) 1.42
Turning predator into prey - the problem of predatory journals. J R Coll Physicians Edinb (2017) 1.39
Letter: Cross-sensitivity between practolol and other beta-blockers? Br Med J (1976) 1.39
Quality criteria for early signals of possible adverse drug reactions. Lancet (1990) 1.33
Benoxaprofen: side-effect profile in 300 patients. Br Med J (Clin Res Ed) (1982) 1.28
Can pharmacogenetics help rescue drugs withdrawn from the market? Pharmacogenomics (2006) 1.27
Why hypertensive patients vary in their response to oral debrisoquine. Br Med J (1977) 1.25
The clinical case report: a review of its merits and limitations. BMC Res Notes (2014) 1.21
Letter: Skin reactions to practolol. Br Med J (1974) 1.21
Maternal valproic acid and congenital neural tube defects. Lancet (1982) 1.20
The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France. Pharmacoepidemiol Drug Saf (2006) 1.20
Long QT syndrome during high-dose cisapride. Arch Intern Med (1995) 1.20
Pharmacokinetics of perhexiline maleate in anginal patients with and without peripheral neuropathy. Eur J Clin Pharmacol (1978) 1.18
Case reports of suspected adverse drug reactions: case reports were dismissed too quickly. BMJ (2006) 1.17
Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med (2016) 1.11
Jaundice associated with the use of benoxaprofen. Lancet (1982) 1.03
An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making. BMJ Open (2014) 1.02
Comparison of 500 spontaneous and 500 published reports of adverse drug reactions. Eur J Clin Pharmacol (1990) 1.00
Drug induced liver injury: accuracy of diagnosis in published reports. Ann Hepatol (2014) 1.00
Terodiline for treating detrusor instability in elderly people. BMJ (1991) 0.99
Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose. Br J Clin Pharmacol (2002) 0.98
Benoxaprofen. Br Med J (Clin Res Ed) (1982) 0.97
Is spontaneous reporting always the most important information supporting drug withdrawals for pharmacovigilance reasons in France? Pharmacoepidemiol Drug Saf (2012) 0.97
Proceedings: A correlation between the response to debrisoquine and the amount of unchanged drug excreted in the urine. Br J Pharmacol (1975) 0.97
Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine. Drug Metab Dispos (2014) 0.95
Inheritance of phenytoin hypometabolism: a kinetic study of one family. Clin Pharmacol Ther (1980) 0.95
Pharmacokinetic studies of benoxaprofen in geriatric patients. Eur J Rheumatol Inflamm (1982) 0.95
Thalidomide, drug safety and early drug regulation in the UK. Adverse Drug React Toxicol Rev (2001) 0.90
Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status. Pharmacogenetics (2003) 0.88
Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. Jpn J Clin Oncol (2012) 0.86
An instructive example of a long-latency adverse drug reaction--sclerosing peritonitis due to practolol. Pharmacoepidemiol Drug Saf (2007) 0.82
Drug-induced hepatotoxicity: pharmacokinetic perspectives and strategies for risk reduction. Adverse Drug React Toxicol Rev (1999) 0.81
Practolol and ocular toxicity. Antibodies in serum and tears. Br J Ophthalmol (1976) 0.79
Sources of information used by regulatory agencies on the generation of drug safety alerts. Eur J Clin Pharmacol (2013) 0.78
Letter: Cross-sensitivity between practolol and other beta-blockers? Br Med J (1976) 0.78
[Syncopes and electrocardiographic changes caused by prenylamine]. Ann Cardiol Angeiol (Paris) (1972) 0.77
Post-Marketing Regulation of Medicines Withdrawn from the Market Because of Drug-Attributed Deaths: An Analysis of Justification. Drug Saf (2017) 0.76
Letter: Practolol and the eye. Br Med J (1974) 0.76
[Safety analysis of eight patients treated with erlotinib after severe gefitinib-induced liver injury]. Gan To Kagaku Ryoho (2010) 0.76
Adverse Drug Event Causality Analysis (ADECA): A Process for Evaluating Evidence and Assigning Drugs to Risk Categories for Sudden Death. Drug Saf (2017) 0.76
ADVERSE DRUG REACTION REPORTING URGED AS FACTOR IN ACCREDITATION. Mod Hosp (1964) 0.76
Lack of essential information in spontaneous reports of adverse drug reactions in Catalonia-a restraint to the potentiality for signal detection. Eur J Clin Pharmacol (2017) 0.76
An apparent fatal overdose of terodiline. J Anal Toxicol (1989) 0.76
Cardiac toxicity with cisapride. Pediatr Nurs (1996) 0.75
Case reports and drug safety. Drug Saf (2006) 0.75
Case reports of suspected adverse drug reactions: case reports generate signals efficiently. BMJ (2006) 0.75